Prsentation PowerPoint

1
Early diagnosis of Macular Degeneration
(AMD) Photon Biomed
2
Normal vision allows to contemplate these
celestial objects, but
30 of population 75 years old and over will have
this vision problem
Source Yanoff Ophthalmology, First Edition,
1999 Clinical Practice Guidelines
3
Expected US population
Years of age
Source U.S. Census Bureau, 2004
4
Expected US population suffering AMD
AMD affects 12 millions Americans and it will
increase
Source U.S. Census Bureau, 2004, Beaver Dam
Study - Source Yanoff Ophthalmology, First
Edition, 1999 Clinical Practice Guidelines
5
The Clinical Need

• Cruciality of AMD early diagnosis
• AMD is currently only detectable when damages
  are already present.
• Patient can loose vision in 3 months.
• Medicine can slow or reverse the disease
  progress.

Damage to the central part of the retina will
affect 30 of people 75 and over
There is an urgent need for an efficient way of
making early diagnosis
Source Yanoff Ophthalmology, First Edition,
1999 Clinical Practice Guidelines
6
Early Diagnosis

• Subtle molecular changes take place in the
  macula before any damage appears.
• Metabolic imaging, or molecular mapping, of the
  optic nerve and retina is clearly the next big
  thing in diagnostic technologies for the eye
• - John Flanagan, Toronto Western Research
  Institute
• A non-invasive, convenient and painless method
  to assess early stages of retinal diseases would
  have a significant impact both clinically and
  financially.
• The differentiating factor with Photons
  technology is the ability to collect
  spectroscopic information related to tissue
  parameters such as oxygenation, non-invasively
  and quickly.
• - Lorenzo Leonardi, Institute for Biodiagnostic,
  National Research Council of Canada

7
Oxygen in Finger Tip
Ischemic
The Background Technology

• A new spectral camera able to identify the
  molecular content in each point of an object.
• It is the most efficient spectral imaging system
  in existence.
• Originally developed at Caltech by Photon etcs
  founder, Sebastien Blais-Ouellette
• Used successfully in many fields for the last 5
  years in

Normal
Hyperspectral Camera
Tunable Source

• Astronomy
• Raman Spectroscopy
• Clean Tech
• Dermatology

8
Photon Biomed The Spin-off

• To maximize the efficiency and reduce the time to
  market, we have created Photon Biomed to
• Build a partnership that can accelerate the
  development
• Build a dedicated team that can execute
• Build on
• Photon etcs hyperspectral technology,
• Experienced management,
• Scientific board,
• Key tech personal,
• Sufficient resources.
• Regroup all biomed projects (dermatology,
  endoscopy, quantum dots imager for cancer
  detection).

9
The Market

• Screening instruments for optometrists
• Diagnosis aid instrument for ophthalmologists
• We can sell to
• 100,000 optometrists in the US and Canada _at_
  20,000 each
• 18,000 ophthalmologists in US and Canada _at_
  50,000 each
• It is a worldwide 6 Billion Market
• Drugs that slows down AMD cost 900 per
  treatment, 9 times a year
• Each month that is gained on the diagnosis
  potentially adds 200 Millions in pharmaceutical
  revenue.

10
Conclusion
A great market, an effective team, a breakthrough
technology a great opportunity
Currently, there is no technology in the market
which resembles the Photon device. That gives the
company a first to market advantage. - Lorenzo
Leonardi, Institute for Biodiagnostic, National
Research Council of Canada